To ask Her Majesty’s Government, further to the Written Answers by the Parliamentary Under-Secretary of State for Public Health, Jane Ellison, on 11 September (HC Deb, cols 664–5W) and on 12 September (HC Deb, col 750W), how the assessment was made that if "mitochondria donation was permitted in treatment it is not anticipated that this will impact on the incidence of ovarian hyperstimulation syndrome" in the absence of an evidence base to predict the cohort of patients that may develop ovarian hyperstimulation syndrome.
Answered on
17 November 2014
Further to answers given on 12 September (HC Deb, col 750w) the Human Fertilisation and Embryology Authority (HFEA) has advised that if mitochondrial donation was permitted in treatment it is not anticipated that this would impact on the incidence of ovarian hyper stimulation syndrome (OHSS). This is because any egg donation or collection processes necessary for mitochondrial donation would be carried out at HFEA licensed fertility clinics in line with the guidance outlined in the HFEA Code of Practice. Mitochondrial donation raises no new issues in respect of OHSS as the women who may donate eggs will be subject to the same protocols as those donating to fertility treatment.